Study S002790

A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06256562
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 340
Start: 2023-06-08
Primary completion: 2024-06-05
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Obesity; Overweight
Interventions: DRUG:GZR18; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent (%) change from baseline in body weight at the end of the study (W30) [30 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002409	Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Ji L, Signal transduction and targeted therapy	2026	Randomized trial	PMID 41760612 DOI	cites ClinicalTrials.gov:NCT06256562; registry reference DERIVED:41760612